Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
复制标题
DOI：
10.1016/s1470-2045(21)00155-8
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Wolf I
中科院分区：
文献类型：
--
作者：
Waissengrin B;Agbarya A;Safadi E;Padova H;Wolf I
2020 年 12 月 20 日，以色列卫生部启动了全国性的 COVID-19 疫苗接种活动，旨在于 2021 年 1 月底之前使用辉瑞 BNT162b2 mRNA 疫苗快速为所有高危人群接种疫苗。
On Dec 20, 2020, the Israeli Ministry of Health launched a national COVID-19 vaccination campaign that aimed to rapidly vaccinate all high-risk individuals by the end of January, 2021, using the Pfizer BNT162b2 mRNA vaccine.